FDA Critical Path Office Would Define Up To Four “Opportunities” Per Year
This article was originally published in The Gray Sheet
Executive Summary
FDA envisions creating an Office of Critical Path Opportunities over the next few months to coordinate with industry, academics, clinicians and the general public in proposing an annual list of translational research priorities to spur product development